Assessment of the Appropriateness of Antimicrobial Use in US Hospitals | Infectious Diseases | JAMA Network Open | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
US Department of Health and Human Services, Centers for Disease Control and Prevention. Core elements of hospital antibiotic stewardship programs. Published 2019. Accessed May 21, 2020. https://www.cdc.gov/antibiotic-use/healthcare/pdfs/hospital-core-elements-H.pdf
2.
The White House. National strategy for combating antibiotic-resistant bacteria. Published September 2014. Accessed May 19, 2020. https://www.cdc.gov/drugresistance/pdf/carb_national_strategy.pdf
3.
The White House. National action plan for combating antibiotic-resistant bacteria. Published March 2015. Accessed May 19, 2020. https://www.cdc.gov/drugresistance/pdf/national_action_plan_for_combating_antibotic-resistant_bacteria.pdf
4.
US Centers for Disease Control and Prevention. Antimicrobial use and resistance module. Accessed May 21, 2020. https://www.cdc.gov/nhsn/acute-care-hospital/aur/index.html
5.
Baggs  J, Fridkin  SK, Pollack  LA, Srinivasan  A, Jernigan  JA.  Estimating national trends in inpatient antibiotic use among US hospitals from 2006 to 2012.   JAMA Intern Med. 2016;176(11):1639-1648. doi:10.1001/jamainternmed.2016.5651 PubMedGoogle ScholarCrossref
6.
Goodman  KE, Cosgrove  SE, Pineles  L,  et al.  Significant regional differences in antibiotic use across 576 U.S. hospitals and 11,701,326 million adult admissions, 2016–2017.   Clin Infect Dis. 2020;ciaa570. doi:10.1093/cid/ciaa570 PubMedGoogle Scholar
7.
Spivak  ES, Cosgrove  SE, Srinivasan  A.  Measuring appropriate antimicrobial use: attempts at opening the black box.   Clin Infect Dis. 2016;63(12):1639-1644.PubMedGoogle Scholar
8.
Magill  SS, Edwards  JR, Bamberg  W,  et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team.  Multistate point-prevalence survey of health care-associated infections.   N Engl J Med. 2014;370(13):1198-1208. doi:10.1056/NEJMoa1306801 PubMedGoogle ScholarCrossref
9.
Magill  SS, Edwards  JR, Beldavs  ZG,  et al; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team.  Prevalence of antimicrobial use in US acute care hospitals, May-September 2011.   JAMA. 2014;312(14):1438-1446. doi:10.1001/jama.2014.12923 PubMedGoogle ScholarCrossref
10.
Magill  SS, O’Leary  E, Janelle  SJ,  et al; Emerging Infections Program Hospital Prevalence Survey Team.  Changes in prevalence of health care–associated infections in U.S. hospitals.   N Engl J Med. 2018;379(18):1732-1744. doi:10.1056/NEJMoa1801550 PubMedGoogle ScholarCrossref
11.
Magill  SS, O’Leary  E, Ray  SM,  et al; Emerging Infections Program Hospital Prevalence Survey Team.  Antimicrobial use in US hospitals: comparison of results from Emerging Infections Program prevalence surveys, 2015 and 2011.   Clin Infect Dis. 2020;ciaa373. doi:10.1093/cid/ciaa373 PubMedGoogle Scholar
12.
Dean  AG, Sullivan  KM, Soe  MM. OpenEpi: open source epidemiologic statistics for public health, version 3.01. Updated April 6, 2013. Accessed January 22, 2021. http://www.OpenEpi.com
13.
Fagan  R, Gualandi  N, Beldavs  ZG,  et al. Developing an approach to evaluating the quality of antibiotic prescribing in hospitalized patients with community-acquired pneumonia (CAP) and non-catheter associated urinary tract infection (UTI). Poster 137 presented at: IDWeek; October 8-12, 2014; Philadelphia, PA. Accessed May 21, 2020. https://idsa.confex.com/idsa/2014/webprogram/Paper46797.html
14.
Epstein  L, O’Leary  EN, Abanyie-Bimbo  F,  et al. Development of an antimicrobial prescribing quality evaluation pathway for adult patients with community-acquired pneumonia. Poster 328 presented at: Society for Healthcare Epidemiology of America Spring Conference; April 18-20, 2018; Portland, OR.
15.
Abanyie-Bimbo  F, O'Leary  E, Nadle  J,  et al. Evaluation of vancomycin prescribing quality in hospitalized pediatric patients. Poster 275 presented at: IDWeek; October 3-7, 2018; San Francisco, CA. Accessed May 21, 2020. https://idsa.confex.com/idsa/2018/webprogram/Paper69112.html
16.
Mandell  LA, Wunderink  RG, Anzueto  A,  et al; Infectious Diseases Society of America; American Thoracic Society.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.   Clin Infect Dis. 2007;44(suppl 2):S27-S72. doi:10.1086/511159 PubMedGoogle ScholarCrossref
17.
Metlay  JP, Waterer  GW, Long  AC,  et al.  Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America.   Am J Respir Crit Care Med. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST PubMedGoogle ScholarCrossref
18.
Gupta  K, Hooton  TM, Naber  KG,  et al; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.   Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257 PubMedGoogle ScholarCrossref
19.
Stevens  DL, Bisno  AL, Chambers  HF,  et al; Infectious Diseases Society of America.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.   Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu296 PubMedGoogle ScholarCrossref
20.
Solomkin  JS, Mazuski  JE, Bradley  JS,  et al.  Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.   Clin Infect Dis. 2010;50(2):133-164. doi:10.1086/649554 PubMedGoogle ScholarCrossref
21.
Trivedi  KK, Bartash  R, Letourneau  AR,  et al; Partnership for Quality Care (PQC) Inpatient Antimicrobial Stewardship Working Group.  Opportunities to improve antibiotic appropriateness in U.S. ICUs: a multicenter evaluation.   Crit Care Med. 2020;48(7):968-976. doi:10.1097/CCM.0000000000004344 PubMedGoogle Scholar
22.
Tribble  AC, Lee  BR, Flett  KB,  et al; Sharing Antimicrobial Reports for Pediatric Stewardship (SHARPS) Collaborative.  Appropriateness of antibiotic prescribing in United States children’s hospitals: a national point prevalence survey.  Published online January 16, 2020.  Clin Infect Dis. 2020;71(8):e226-e234. doi:10.1093/cid/ciaa036 PubMedGoogle ScholarCrossref
23.
McMullan  BJ, Hall  L, James  R,  et al.  Antibiotic appropriateness and guideline adherence in hospitalized children: results of a nationwide study.   J Antimicrob Chemother. 2020;75(3):738-746. doi:10.1093/jac/dkz474PubMedGoogle Scholar
24.
National Centre for Antimicrobial Stewardship and Australian Commission on Safety and Quality in Health Care. Antimicrobial prescribing practice in Australian hospitals: results of the 2018 Hospital National Antimicrobial Prescribing Survey. Published January 2020. Accessed January 21, 2021. https://irp-cdn.multiscreensite.com/d820f98f/files/uploaded/Hospital%20NAPS%20Public%20Report%20-%202018.pdf
25.
Rybak  MJ, Le  J, Lodise  TP,  et al.  Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.   Am J Health Syst Pharm. 2020;77(11):835-864. doi:10.1093/ajhp/zxaa036 PubMedGoogle ScholarCrossref
26.
Madaras-Kelly  KJ, Burk  M, Caplinger  C,  et al; Pneumonia Duration of Therapy Medication Utilization Evaluation Group.  Total duration of antimicrobial therapy in veterans hospitalized with uncomplicated pneumonia: results of a national medication utilization evaluation.   J Hosp Med. 2016;11(12):832-839. doi:10.1002/jhm.2648 PubMedGoogle ScholarCrossref
27.
Vaughn  VM, Flanders  SA, Snyder  A,  et al.  Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study.   Ann Intern Med. 2019;171(3):153-163. doi:10.7326/M18-3640 PubMedGoogle ScholarCrossref
28.
Yi  SH, Hatfield  KM, Baggs  J,  et al.  Duration of antibiotic use among adults with uncomplicated community-acquired pneumonia requiring hospitalization in the United States.   Clin Infect Dis. 2018;66(9):1333-1341. doi:10.1093/cid/cix986 PubMedGoogle ScholarCrossref
29.
Nicolle  LE, Gupta  K, Bradley  SF,  et al.  Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America.   Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciz021 PubMedGoogle ScholarCrossref
30.
Fridkin  S, Baggs  J, Fagan  R,  et al; Centers for Disease Control and Prevention (CDC).  Vital signs: improving antibiotic use among hospitalized patients.   MMWR Morb Mortal Wkly Rep. 2014;63(9):194-200.PubMedGoogle Scholar
31.
Spivak  ES, Burk  M, Zhang  R,  et al; Management of Urinary Tract Infections Medication Use Evaluation Group.  Management of bacteriuria in Veterans Affairs hospitals.   Clin Infect Dis. 2017;65(6):910-917. doi:10.1093/cid/cix474 PubMedGoogle ScholarCrossref
32.
Hartley  SE, Kuhn  L, Valley  S,  et al.  Evaluating a hospitalist-based intervention to decrease unnecessary antimicrobial use in patients with asymptomatic bacteriuria.   Infect Control Hosp Epidemiol. 2016;37(9):1044-1051. doi:10.1017/ice.2016.119 PubMedGoogle ScholarCrossref
33.
Keller  SC, Feldman  L, Smith  J, Pahwa  A, Cosgrove  SE, Chida  N.  The use of clinical decision support in reducing diagnosis of and treatment of asymptomatic bacteriuria.   J Hosp Med. 2018;13(6):392-395. doi:10.12788/jhm.2892PubMedGoogle Scholar
34.
Daniel  M, Keller  S, Mozafarihashjin  M, Pahwa  A, Soong  C.  An implementation guide to reducing overtreatment of asymptomatic bacteriuria.   JAMA Intern Med. 2018;178(2):271-276. doi:10.1001/jamainternmed.2017.7290 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    Infectious Diseases
    March 18, 2021

    Assessment of the Appropriateness of Antimicrobial Use in US Hospitals

    Author Affiliations
    • 1Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
    • 2Lantana Consulting Group, Thetford, Vermont
    • 3Department of Medicine, Emory University, Atlanta, Georgia
    • 4Georgia Emerging Infections Program, Decatur
    • 5Tennessee Department of Health, Nashville
    • 6Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee
    • 7Department of Infectious Diseases, Western Health, Melbourne, Victoria, Australia
    • 8Colorado Department of Public Health and Environment, Denver
    • 9Medical Epidemiology Consulting, Denver, Colorado
    • 10Department of Healthcare Management, University of Denver, Colorado
    • 11Minnesota Department of Health, St Paul
    • 12Hennepin County Public Health, Minneapolis, Minnesota
    • 13California Emerging Infections Program, Oakland
    • 14New Mexico Department of Health, Santa Fe
    • 15Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland
    • 16Infection Prevention and Control Department, University of New Mexico Hospital, Albuquerque
    • 17Oregon Health Authority, Portland
    • 18Connecticut Emerging Infections Program, Hartford and New Haven
    • 19Department of Medicine, Columbia–New York Presbyterian Hospital
    • 20Maryland Department of Health, Baltimore
    • 21University of Maryland Baltimore County, Baltimore
    • 22New York Emerging Infections Program, Rochester
    • 23University of Rochester Medical Center, Rochester, New York
    JAMA Netw Open. 2021;4(3):e212007. doi:10.1001/jamanetworkopen.2021.2007
    Key Points

    Question  What percentage of hospital antimicrobial use in the US deviates from recommended practices, such as treatment selection or duration, on the basis of medical record documentation?

    Findings  In this cross-sectional study of 1566 patients at 192 hospitals, antimicrobial use deviated from recommended practices for 55.9% of patients who received antimicrobials for community-acquired pneumonia or urinary tract infection present at admission or who received fluoroquinolone or intravenous vancomycin treatment.

    Meaning  The findings suggest that standardized assessments of hospital antimicrobial prescribing quality can be used to estimate the appropriateness of antimicrobial use in large groups of hospitals.

    Abstract

    Importance  Hospital antimicrobial consumption data are widely available; however, large-scale assessments of the quality of antimicrobial use in US hospitals are limited.

    Objective  To evaluate the appropriateness of antimicrobial use for hospitalized patients treated for community-acquired pneumonia (CAP) or urinary tract infection (UTI) present at admission or for patients who had received fluoroquinolone or intravenous vancomycin treatment.

    Design, Setting, and Participants  This cross-sectional study included data from a prevalence survey of hospitalized patients in 10 Emerging Infections Program sites. Random samples of inpatients on hospital survey dates from May 1 to September 30, 2015, were identified. Medical record data were collected for eligible patients with 1 or more of 4 treatment events (CAP, UTI, fluoroquinolone treatment, or vancomycin treatment), which were selected on the basis of common infection types reported and antimicrobials given to patients in the prevalence survey. Data were analyzed from August 1, 2017, to May 31, 2020.

    Exposure  Antimicrobial treatment for CAP or UTI or with fluoroquinolones or vancomycin.

    Main Outcomes and Measures  The percentage of antimicrobial use that was supported by medical record data (including infection signs and symptoms, microbiology test results, and antimicrobial treatment duration) or for which some aspect of use was unsupported. Unsupported antimicrobial use was defined as (1) use of antimicrobials to which the pathogen was not susceptible, use in the absence of documented infection signs or symptoms, or use without supporting microbiologic data; (2) use of antimicrobials that deviated from recommended guidelines; or (3) use that exceeded the recommended duration.

    Results  Of 12 299 patients, 1566 patients (12.7%) in 192 hospitals were included; the median age was 67 years (interquartile range, 53-79 years), and 864 (55.2%) were female. A total of 219 patients (14.0%) were included in the CAP analysis, 452 (28.9%) in the UTI analysis, 550 (35.1%) in the fluoroquinolone analysis, and 403 (25.7%) in the vancomycin analysis; 58 patients (3.7%) were included in both fluoroquinolone and vancomycin analyses. Overall, treatment was unsupported for 876 of 1566 patients (55.9%; 95% CI, 53.5%-58.4%): 110 of 403 (27.3%) who received vancomycin, 256 of 550 (46.5%) who received fluoroquinolones, 347 of 452 (76.8%) with a diagnosis of UTI, and 174 of 219 (79.5%) with a diagnosis of CAP. Among patients with unsupported treatment, common reasons included excessive duration (103 of 174 patients with CAP [59.2%]) and lack of documented infection signs or symptoms (174 of 347 patients with UTI [50.1%]).

    Conclusions and Relevance  The findings suggest that standardized assessments of hospital antimicrobial prescribing quality can be used to estimate the appropriateness of antimicrobial use in large groups of hospitals. These assessments, performed over time, may inform evaluations of the effects of antimicrobial stewardship initiatives nationally.

    ×